While big pharma firms are expected to make the big splash in immuno-oncology at the upcoming American Society of Clinical Oncology (ASCO) meeting, small biotech Armo Biosciences Inc. also will be on hand with a poster on AM0010, a promising interleukin-10 (IL-10)-targeting immunotherapy that helped the Redwood City, Calif.-based firm attract $30 million in series B funding.